[Neuroleptic malignant syndrome].
The Neuroleptic Malignant Syndrome (NMS) is characterized e.g.: by increased muscular tone, fever. NMS is the complication during neuroleptic therapy. The base of NMS are changes in the neurotransmitters. The course of NMS is usually typical. Complete NMS develops in a few hours. The course NMS depends on type of the neuroleptic and way of reception. The symptoms of NMS usually remain for several days. Rapid diagnosis and proper treatment are very important for prognosis. People who survived critical state of NMS have good life prognosis but poor outcome (since the return to neuroleptic therapy is impossible). NMS as a subject has an increasing significance because of more frequent usage of neuroleptic in general medicine.
Murak
E
E
Ze Specjalistycznego Psychiatrycznego ZOZ w Lodzi.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D009129:Muscle Tonus / Q000187:drug effects; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D018377:Neurotransmitter Agents / Q000378:metabolism; D011379:Prognosis
D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents; D001569:Benzodiazepines; D001971:Bromocriptine; D007980:Levodopa; D003620:Dantrolene
Złośliwy zespół neuroleptyczny.